BPH/LUTS and ED: Common pharmacological pathways for a common treatment

Journal of Sexual Medicine

Volumn 10, Issue 10, 2013, Pages 2382-2393

  Fusco, Ferdinando ^a,e   D'Anzeo, Gianluca ^b   Sessa, Aurelio ^c   Pace, Gianna ^d   Rossi, Andrea ^b   Capece, Marco ^a   d'Emmanuele di Villa Bianca, Roberta ^a,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Medical Department   (Italy)

^c Italian College of General Practitioners   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

BPH; ED; LUTS; Phosphodiesterase Type 5 Treatments; Treatments

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLIC GMP; CYSTEINE; HYDROGEN SULFIDE; INOSITOL TRISPHOSPHATE; MIRABEGRON; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PHOSPHOLIPASE C; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; VARDENAFIL; YOHIMBINE;

ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED CLINICAL TRIAL (TOPIC); CORPUS CAVERNOSUM; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; GYNECOMASTIA; HUMAN; HYPOTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; MYALGIA; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RHINOPHARYNGITIS; SARCOPLASMIC RETICULUM; SEXUAL DYSFUNCTION; SIDE EFFECT; SMOOTH MUSCLE TONE; TREATMENT DURATION; URINE FLOW RATE; XEROSTOMIA;

BPH; ED; LUTS; PHOSPHODIESTERASE TYPE 5 TREATMENTS; TREATMENTS;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 84885939282     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12261     Document Type: Review

References (60)

1. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
3. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-1138.
4. Norg RJ, Portegijs PJ, van de Beek K, van Schayck O, Knottnerus JA. A decision aid for GPs for the treatment of elderly male patients with lower urinary tract symptoms (LUTS). Fam Pract 2006;23:666-673.
5. Parsons BA, Bright E, Shaban AM, Whitehouse A, Drake MJ. The role of invasive and non-invasive urodynamics in male voiding lower urinary tract symptoms. World J Urol 2011;29:191-197.
6. Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Mocada I. Current benign prostatic hyperplasia treatment: Impact on sexual function and management of related sexual adverse events. Int J Clin Pract 2011;65:1005-1013.
7. National Institutes of Health. NIH Consensus Development Panel of Impotence. JAMA 1993;270:83-90.
8. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
9. Miner MM, Kuritzky L. Erectile dysfunction: A sentinel marker for cardiovascular disease in primary care. Cleve Clin J Med 2007;74(suppl 3):S30-37.
10. Broderick GA. Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. Rev Urol 2003;5(suppl 7):S9-20.
11. Speakman MJ. PDE5 inhibitors in the treatment of LUTS. Curr Pharm Des 2009;15:3502-3505.
12. Orabi H, Albersen M, Lue TF. Association of lower urinary tract symptoms and erectile dysfunction: Pathophysiological aspects and implications for clinical management. Int J Impot Res 2011;23:99-108.
13. Gacci M, Eardley I, Giuliano F, Hatzicristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-825.
14. Demir O, Akgul K, Akar Z, Cakmak O, Ozdemir I, Bolukbasi A, Can E, Gumus BH. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009;12:29-34.
15. Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007;19:386-392.
16. Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Ayier LP. The impact of lower urinary tract symptoms on male sexual health: Epi LUTS. BJU Int 2009;103(suppl 3):33-41.
17. Köhler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009;55:38-48.
18. Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res 2007;19:544-550.
19. Laydner HK, Oliveira P, Oliveira CR, Makarawo TP, Andrade WS, Tannus M, Araújo JL. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review. BJU Int 2011;107:1104-1109.
20. Azadzoi KM, Chen BG, Radisavljevic ZM, Siroky MB. Molecular reactions and ultrastructural damage in the chronically ischemic bladder. J Urol 2011;186:2115-2122.
21. Zhang XH, Melman A, DiSanto ME. Update on corpus cavernosum smooth muscle contractile pathways in erectile function: A role for testosterone? J Sex Med 2011;8:1865-1879.
22. Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007;26(6 suppl):948-954.
23. Tam SW, Worcel M, Wyllie M. Yohimbine: A clinical review. Pharmacol Ther 2001;91:215-243.
24. Senbel AM, Mostafa T. Yohimbine enhances the effect of sildenafil on erectile process in rats. Int J Impot Res 2008;20:409-417.
25. Giuliano F. Lower urinary tract symptoms and sexual dysfunction: A common approach. BJU Int 2008;101(suppl 3):22-26.
26. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-1723.
27. Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: An in vitro study. Int J Urol 2008;15:1072-1076.
28. Limberg BJ, Andersson KE, Aura Kullmann F, Burmer G, de Groat WC, Rosenbaum JS. β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 2010;342:295-306.
29. 3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanism in human corpus cavernosum function. PNAS 2003;100:5531-5536.
30. Giglio D, Tobin G. Muscarinic receptor subtypes in the lower urinary tract. Pharmacology 2009;83:259-269.
31. Senbel AM, Hashad A, Sharabi FM, Daabees TT. Activation of muscarinic receptors inhibits neurogenic nitric oxide in the corpus cavernosum. Pharmacol Res 2012;65:303-211.
32. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006;111:400-423.
33. de Groat WC, Yoshimura N. Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol 2009;194:91-138.
34. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: Critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond) 2011;121:459-488.
35. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R. Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. Am J Physiol Heart Circ Physiol 2004;287:H2316-2323.
36. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J 2011;20:6008-6016.
37. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancaleone V, Cirino G. Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol 2010;30:1998-2004.
38. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, De Palma R, Ignarro LJ, Cirino G. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A 2009;106:4513-4518.
39. Fusco F, d'Emmanuele di Villa Bianca R, Mitidieri E, Cirino G, Sorrentino R, Mirone V. Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: A novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol 2012;62:1174-1180.
40. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone V, Ciro I, Cirino G. Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol 2009;56:378-383.
41. Guo H, Gai JW, Wang Y, Jin HF, Du JB, Jin J. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells. Urology 2012;79:483.e1-4835.
42. Jung JH, Jae SU, Kam SC, Hyun JS. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: Impact of treatment of LUTS on sexual function. J Sex Med 2009;6:2299-2304.
43. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
44. McVary K, Roehrborn C, Kaminetsky J, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms (LUTS) secondary to benign prostatichyperplasia (BPH). J Urol 2007;177:1401-1407.
45. Eryildirim B, Aktas A, Kuyumcuoglu U, Faydaci G, Tarhan F, Ozgül A. The effectiveness of sildenafil citrate in patients with erectile dysfunction and lower urinary system symptoms and the significance of asymptomatic inflammatory prostatitis. Int J Impot Res 2010;22:349-354.
46. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:1228-1234.
47. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009;56:727-735.
48. Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study. BJU Int 2011;107:1110-1116.
49. Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010;183:1092-1097.
50. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ. Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-281.
51. Kim TB, Kim KH, Yoon SJ. Open-label, intermittent dose, prospective study evaluating the effects of tadalafil on lower urinary tract symptoms and erectile function in patients with benign prostatic hyperplasia: Continuation and durability of effects. Int Neurourol J 2010;14:7-12.
52. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-925.
53. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-1244.
54. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-1458.
55. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-507.
56. Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A systematic review and meta-analysis. Urology 2011;77:123-129.
57. Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW, Yoo TK, Choi HY, Park HY, Lee SW. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: A multicenter, prospective study. J Androl 2012;33:397-403.
58. Roehrborn CG. Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004;6:121-127.
59. Lowe G, Costabile RA. 10-year analysis of adverse event reports to the food and drug administration for phosphodiesterase type-5 inhibitors. J Sex Med 2012;9:265-270.
60. Mirone V, d'Emmanuele di Villa Bianca R, Mitidieri E, Imbimbo C, Fusco F, Verze P, Vitale DF, Sorrentino R, Cirino G. Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: A randomized placebo-controlled study. Eur Urol 2009;56:1067-1073.